Jeffrey Hung Analyst Performance

Analyst at Morgan Stanley

Jeffrey Hung is a stock analyst at Morgan Stanley in the medical sector, covering 29 publicly traded companies. Over the past year, Jeffrey Hung has issued 38 stock ratings, including buy, hold, and sell recommendations. While full access to Jeffrey Hung's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jeffrey Hung's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 74 Last 9 Years
Buy Recommendations: 66.22% 49 Buy Ratings
Companies Covered: 29 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	66.2%	49 ratings
Hold	29.7%	22 ratings
Sell	4.1%	3 ratings

Out of 74 total stock ratings issued by Jeffrey Hung at Morgan Stanley, the majority (66.2%) have been Buy recommendations, followed by 29.7% Hold and 4.1% Sell.

Best & Worst Calls

Best Call
0000.0%
MYOK
Dec 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
SELB
Dec 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	96.6% of companies on NASDAQ	28 companies
NYSE	3.4% of companies on NYSE	1 company

Jeffrey Hung, an analyst at Morgan Stanley, currently covers 29 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 29 companies	100.0%

Jeffrey Hung of Morgan Stanley specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 18 companies	62.1%
MED - DRUGS 4 companies	13.8%
PHARMACEUTICAL PREPARATIONS 4 companies	13.8%
BIOTECHNOLOGY 2 companies	6.9%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	3.4%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
RYTM Rhythm Pharmaceuticals	9/24/2025	Boost Price Target	$98.68	$122.00	Overweight
JAZZ Jazz Pharmaceuticals	9/24/2025	Boost Price Target	$129.40	$167.00	Overweight
CGON CG Oncology	9/17/2025	Boost Price Target	$38.54	$79.00	Overweight
ENGN enGene	9/12/2025	Lower Price Target	$6.04	$18.00	Overweight
NBIX Neurocrine Biosciences	9/5/2025	Boost Price Target	$140.40	$163.00	Overweight
JAZZ Jazz Pharmaceuticals	8/28/2025	Boost Price Target	$124.12	$163.00	Overweight
PTCT PTC Therapeutics	8/20/2025	Lower Price Target	$48.61	$71.00	Overweight
ERAS Erasca	8/18/2025	Reiterated Rating	$1.64	$2.00	Equal Weight
CTNM Contineum Therapeutics	8/18/2025	Boost Price Target	$7.38	$21.00	Overweight
CGEM Cullinan Therapeutics	8/18/2025	Lower Price Target	$7.74	$28.00	Overweight
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
BCYC Bicycle Therapeutics	8/12/2025	Lower Price Target	$7.46	$13.00	Equal Weight
JAZZ Jazz Pharmaceuticals	8/6/2025	Lower Price Target	$108.12	$162.00	Overweight
NBIX Neurocrine Biosciences	7/31/2025	Boost Price Target	$129.40	$158.00	Overweight
JAZZ Jazz Pharmaceuticals	7/22/2025	Lower Price Target	$114.72	$165.00	Overweight
NBIX Neurocrine Biosciences	7/22/2025	Boost Price Target	$132.79	$150.00	Overweight
FOLD Amicus Therapeutics	7/17/2025	Upgrade	$6.07		Overweight
RARE Ultragenyx Pharmaceutical	7/14/2025	Lower Price Target	$29.51	$55.00	Overweight
CGON CG Oncology	6/17/2025	Boost Price Target	$26.26	$56.00	Overweight
ACAD ACADIA Pharmaceuticals	5/20/2025	Set Price Target	$21.99	$24.00	Equal Weight
CTNM Contineum Therapeutics	5/19/2025	Lower Price Target	$3.71	$20.00	Overweight
CGON CG Oncology	5/19/2025	Lower Price Target	$24.86	$52.00	Overweight
RARE Ultragenyx Pharmaceutical	5/9/2025	Boost Price Target	$35.87	$65.00	Overweight
JAZZ Jazz Pharmaceuticals	5/7/2025	Lower Price Target	$104.98	$166.00	Overweight
ENGN enGene	3/11/2025	Lower Price Target	$4.97	$34.00	Overweight
IRON Disc Medicine	3/7/2025	Reiterated Rating	$55.34	$85.00	Overweight
CGEM Cullinan Therapeutics	3/7/2025	Reiterated Rating	$8.91	$35.00	Overweight
CTNM Contineum Therapeutics	3/7/2025	Reiterated Rating	$6.43	$25.00	Overweight
CGON CG Oncology	3/7/2025	Reiterated Rating	$26.82	$55.00	Overweight
CNTA Centessa Pharmaceuticals	3/7/2025	Reiterated Rating	$16.31	$27.00	Overweight
BIOA (BIOA)	3/7/2025	Reiterated Rating	$4.53	$5.00	Underweight
ACAD ACADIA Pharmaceuticals	3/7/2025	Reiterated Rating	$17.46	$20.00	Equal Weight
RYTM Rhythm Pharmaceuticals	3/7/2025	Reiterated Rating	$50.86	$72.00	Overweight
PTCT PTC Therapeutics	3/7/2025	Reiterated Rating	$52.09	$70.00	Overweight
NBIX Neurocrine Biosciences	3/7/2025	Reiterated Rating	$113.38	$150.00	Overweight
JAZZ Jazz Pharmaceuticals	3/7/2025	Reiterated Rating	$139.12	$183.00	Overweight
ERAS Erasca	3/7/2025	Reiterated Rating	$1.50	$4.00	Overweight
CYTK Cytokinetics	2/13/2025	Upgrade	$42.18	$67.00	Overweight
NBIX Neurocrine Biosciences	2/4/2025	Boost Price Target	$150.10	$185.00	Overweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.